论文部分内容阅读
AIM To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma(HCC)treated with transarterial chemoembolization combined with sorafenib(TACE-S).METHODS We retrospectively evaluated t